Autoimmune Hypoglycemia in a Patient with Characterization of Insulin Receptor Autoantibodies

Suk Chon1,2*, Moon Chan Choi1*, Yun Jung Lee1, You Cheol Hwang1,2, In-Kyung Jeong1,2, Seungjoon Oh1,2, Kyu Jeung Ahn1,2, Ho Yeon Chung1,2, Jeong-taek Woo1,2, Sung-Woon Kim1,2, Jin-Woo Kim1,2, Young Seol Kim1,2

1Department of Endocrinology and Metabolism, 2Research Institute of Endocrinology, Kyung Hee University School of Medicine, Seoul, Korea

Background: Type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in severe hyperglycemia and acanthosis nigricans. However, the mechanisms by which these autoantibodies induce hypoglycemia are largely unknown. In this paper, we report the case of patient with type B insulin resistance syndrome who presented with frequent severe fasting hypoglycemia and acanthosis nigricans.

Methods: To evaluate the mechanism of hypoglycemia, we measured the inhibition of insulin binding to erythrocytes and IM9 lymphocytes in a sample of the patient's dialyzed serum before and after immunosuppressive therapy.

Results: In the patient's pre-treatment serum IgG, the binding of 125I-insulin to erythrocytes was markedly inhibited in a dose-dependent manner until the cold insulin level reached 10^{-9} mol/L. We also observed dose-dependent inhibition of insulin binding to IM9 lymphocytes, which reached approximately 82% inhibition and persisted even when diluted 1:20. After treatment with glucocorticoids, insulin-erythrocyte binding activity returned to between 70% and 80% of normal, while the inhibition of insulin-lymphocyte binding was reduced by 17%.

Conclusion: We treated a patient with type B insulin resistance syndrome showing recurrent fasting hypoglycemia with steroids and azathioprine. We characterized the patient's insulin receptor antibodies by measuring the inhibition of insulin binding.

Keywords: Autoimmune hypoglycemia; Insulin receptor antibody; Type B insulin resistance

INTRODUCTION

Autoimmune hypoglycemia is a very rare disease caused by autoantibodies to the insulin receptor or to insulin itself [1]. Insulin antibody-mediated hypoglycemia is more common in autoimmune hypoglycemia [2]. Type B insulin resistance syndrome is a rare disorder characterized by severe hyperglycemia and acanthosis nigricans in which autoantibodies to the insulin receptor are present in serum [3]. On review of the literature, there are few cases of spontaneous fasting hypoglycemia reported, which is difficult to distinguish from other causes of hypoglycemia such as insulinoma [4,5]. Insulin receptor antibodies may cause hyperglycemia and/or hypoglycemia, and have been studied in vitro [3,6]. However, the rarity of insulin receptor antibody-mediated hypoglycemia has prevented extensive research into its mechanism.

Recently, we experienced a case of male patient with frequent, severe fasting hypoglycemia and acanthosis nigricans. He had no significant medical history and no history of autoimmune disease. Laboratory evaluation revealed the presence of insulin receptor antibodies in his serum. We treated him with glucocorticoids and azathioprine. In order to evaluate the mechanism of insulin receptor antibody-induced hypoglycemia, we analyzed the behavior of antibodies in his serum.
METHODS

Case history
A 35-year-old man presented with severe, episodic fasting hypoglycemia for the past several months as evidenced by sweating, anxiety, and episodes of unconsciousness. He had gained 12 kg over the past 6 months. His medical history was unremarkable. Physical exam revealed extensive acanthosis nigricans on his posterior neck, axillary, and inguinal areas (Fig. 1). We confirmed the diagnosis of fasting hypoglycemia with an attempted 72-hour fasting test (Fig. 2). At 4 hour after fasting, he complained of hypoglycemic symptoms and his blood glucose level was 44 mg/dL, plasma insulin level was 19.8 μU/mL, plasma proinsulin level was 14.11 pmol/L, and C-peptide was undetectable. The test was terminated after 9 hours due to severe hypoglycemia: his blood glucose level was 38 mg/dL. Despite worsening hypoglycemia, his insulin level slowly decreased and his C-peptide level remained undetectable. We performed computed tomography to exclude the possibility of insulinoma and found no evidence of a pancreatic mass. Percutaneous transhepatic portal and splenic venous sampling did not show abnormally elevated insulin or C-peptide levels. The patient had a normal adrenal response to a rapid ACTH stimulation test and normal thyroid function tests. We performed a 75 g oral glucose tolerance test to evaluate his insulin secretory capacity. Glucose excursion was normal, but insulin and C-peptide secretion increased in a delayed pattern and remained consistently elevated despite a normal glucose level (Fig. 3A).

We analyzed the patient’s serum for autoantibodies to evaluate for associated autoimmune diseases. Serologic exam was unremarkable: tests were negative for rheumatoid factor, antinuclear antibodies, anti-ds DNA antibodies, and anti-thyroid antibodies. Serum immunoglobulin levels (G, A, M, and E) were also within normal limits. Although the level of insulin antibodies was 6.7% (reference range, 0-7%), the insulin receptor antibody was positive by radioreceptor assay.

We obtained written informed consent from the patient and the study protocol was approved by the Institutional Review Board.

Fig. 1. Thickened, hyperpigmented skin lesions (acanthosis nigricans) were observed on the posterior neck, axillae and groin.

Fig. 2. Initial 24-hour glucose profile using a continuous glucose monitoring system during a 72-hour fasting test.

Fig. 3. Pre- and post-treatment serum levels of insulin and C-peptide after 75 g oral glucose tolerance test. (A) On admission. (B) Sixteen-month follow-up.
Board of Kyung Hee University.

Methods

Preparation of the serum IgG fraction
We dialyzed the patient’s serum through a membrane that excluded molecules less than 50,000 MW. The complements in serum were heat-inactivated at 56°C for 30 minutes and then run the dialyzed serum through a protein A affinity column (Hi-Trap affinity column). After washing with 10 mL PBS, the bound IgG was eluted with 3 mL of 100 mM sodium citrate (pH 3.5). We dialyzed the samples again and determined immunoglobulin concentrations.

Insulin binding of erythrocytes
Insulin binding was determined as previously reported [7,8] on freshly isolated erythrocytes drawn under fasting conditions and purified on cellulose columns. Results are expressed as the percent specific binding for an erythrocyte suspension containing 4×10⁶ RBC/μL.

Binding studies
To determine the insulin-erythrocyte binding activity, we performed binding studies using a radioreceptor assay.

We determined the extent of erythrocyte binding to ¹²⁵I-labeled insulin by incubating a 400-μL cell suspension (1.75×10⁶ cells in buffer G), 20 pg of ¹²⁵I-labeled insulin in 25 μL of buffer, and various amounts of unlabeled insulin (0 to 0.5×10⁶ ng) in a total volume of 0.5 mL. After incubation at 15°C for 3 hours, we placed 200 μL aliquots of the suspension into pre-chilled microfuge tubes containing 200 μL buffer G and 200 μL dibutyl phthalate and centrifuged them for 10 minutes in a Beckman Microfuge B (Beckman Instruments Inc., Fullerton, CA, USA). We determined the radioactivity of the cells by gamma counter.

Inhibition of insulin binding of human IM9 lymphocytes
We also investigated the insulin receptor binding activity of human lymphocytes, which carry insulin receptors that reflect insulin sensitivity. We pre-incubated 7.5×10⁶ IM9 cells with serial dilutions of patient serum or control serum at 37°C for 30 minutes in 800 μL assay buffer (100 mM HEPES, 120 mM NaCl, 1.2 mM MgSO₄, 2.4 mM KCl, 1 mM glucose, 1 mM EDTA, 1% bovine serum albumin, pH 7.8). Cells were washed with phosphate-buffered saline and incubated with ¹²⁵I-insulin in a final volume of 500 μL assay buffer at 15°C. At the end of the 90-minute incubation period, we centrifuged cells and separated cell-associated radioactivity from free ¹²⁵I-insulin by adding 200 μL dibutylphthalate [3].

RESULTS

Clinical course
Following the laboratory investigation, we diagnosed the patient with autoimmune hypoglycemia caused by insulin receptor antibodies and treated him with two courses of plasmapheresis. The patient’s symptoms did not improve (Fig. 4A), so
we added immunosuppressive agents. We first treated the patient with prednisolone 80 mg/day, which we eventually tapered to 20 mg/day 11 months after admission. The patient experienced no hypoglycemia attack during prednisolone treatment (Fig. 4B), although he suffered from mild recurrent hypoglycemia and skin inflammation at doses less than 20 mg/day. As a steroid-sparing agent, we added the azathioprine 100 mg/day to a physiologic prednisolone dose of 7.5 mg/day. The patient experienced no hypoglycemia during the 6 months of azathioprine treatment, and his skin inflammation and acanthosis nigricans improved.

We performed a 75 g glucose tolerance test 16 months after admission to measure glucose, insulin, and C-peptide levels (Fig. 3B). Compared to the initial test, the serum glucose level had increased to over 200 mg/dL; both insulin and C-peptide levels had also increased. We also found that the increment of insulin level during the glucose excursion was faster than that of initial test. Currently, our patient is maintained on azathioprine 100 mg/day, and has not experienced any episodes of hypoglycemia.

Analysis of insulin binding of erythrocytes
We compared the insulin receptor binding activity of our patient's pre-treatment serum, post-treatment serum, and normal human serum by adding cold insulin (10^{-12} to 10^{-6} mol/L) to normal human erythrocytes. In the case of the patient's pre-treatment serum, insulin receptor binding activity was inhibited in a dose-dependent manner until the cold insulin level reached 10^{-9} mol/L. This result specifically suggests that the patient's serum contained insulin receptor antibodies. After treatment, binding activity recovered to 70% to 80% of normal (Fig. 5).

Analysis of insulin binding of IM9 lymphocytes
The ability of the patient's serum to inhibit the binding of {^{125}}I-insulin to IM9 lymphocytes is shown in Fig. 6. We measured insulin receptor binding activity by diluting IgG purified from normal human serum, the patient's pre-treatment serum, and the patient's post-treatment serum to 1:20, 1:40, 1:160, 1:320, and 1:640 each in IM9 cell lines. The insulin binding activity of the patient's pre-treatment IgG was reduced in a dose-dependent manner compared to normal IgG. Most dramatically, the 1:20 dilution was 82% inhibited compared to normal IgG. Notably, this inhibitory effect was reduced to 17% after treatment (Fig. 6).

DISCUSSION
Insulin resistance syndrome can be classified into type A, in which insulin receptors are absent, and type B, in which insulin receptor autoantibodies are present in serum [1]. First reported by Kahn et al. [9] in 1976, type B insulin resistance syndrome occurs most often in adult women who show other symptoms of autoimmune disease. It can be diagnosed by detection of insulin receptor antibodies [10,11].

Clinical symptoms can include hyperglycemia, hypoglycemia, hyperinsulinemia, severe insulin resistance, and acantho-
Yamasaki et al. [19] studied a patient with systemic lupus erythematosus by only 17%.

The IgG insulin receptor antibody binds the insulin receptor and can have two different effects. Its function can be either inhibitory (by inhibiting insulin binding) or stimulatory (with an insulin-like action), both resulting in hypoglycemia [5,14,15,17]. These different interactions may be explained by quantitative differences in antibody titers. At low titers, the autoantibody appears to act as a partial agonist and result in hypoglycemia, while at high titers it appears to down-regulate the receptor's response to insulin and result in hyperglycemia [14,18]. In our patient, we measured insulin receptor antibodies by quantifying the inhibition of insulin binding to both erythrocytes and IM9 lymphocytes. However, this method is unable to determine the type of activation caused by autoantibody binding. Therefore, further study is needed to elucidate the mechanism of post-receptor signaling.

In our patient, we observed significant inhibition of insulin binding to erythrocytes and IM9 lymphocytes in a dose-dependent manner, which did not improve after plasmapheresis. Clinically, the patient's symptoms of hypoglycemia and glucose tolerance improved after treatment with prednisolone and azathioprine. We found that insulin binding to erythrocytes gradually normalized to 70% to 80% of normal after immunosuppressive treatment. Furthermore, we found that the patient's dialyzed post-treatment serum inhibited $^{125}\text{I}$-binding to IM9 lymphocytes by only 17%.

Yamasaki et al. [19] studied a patient with systemic lupus erythematosus and type B insulin resistance who showed the rapid disappearance of insulin receptor autoantibodies from circulation according to the treatment. They determined the biological and clinical relevance of the patient's insulin receptor antibodies by analyzing the inhibition of insulin binding to IM9 lymphocytes, the uptake of 2-deoxyglucose in CHO cells, and by phosphotyrosine immunoblotting of the insulin receptor. After immunosuppressive treatment, they found attenuation of the insulin binding inhibition present in the patient's serum in parallel with the normalization of the patient's insulin sensitivity. However, in this report the stimulatory activities that promote 2-deoxyglucose uptake and insulin receptor phosphorylation were discordant with the occurrence of fasting hypoglycemia. Thus, this study implicated other pathogenic mechanisms in the development of fasting hypoglycemia, in addition to the insulin-like action of insulin receptor antibodies.

Our study proved that insulin binding activity was improved after treatment. If our study was further investigated about the post-receptor signaling after autoantibodies were bound to receptors, the mechanism of fasting hypoglycemia was expected to be clearly established.

Immunosuppressants can be used to treat type B insulin resistance. However, the treatment results have generally been unsatisfactory. In our case, the patient's symptoms did not improve after plasmapheresis, leading us to use a combination of steroids and azathioprine, which resulted in clinical improvement. Arioglu et al. [20] reviewed the long-term clinical course of type B insulin resistance syndrome in 24 patients who were followed for up to 28 years. Although they found that the most effective short-term therapy was high-dose steroids, it remains unclear whether patients presenting with hypoglycemia would benefit from long-term steroid treatment. They also reported that immunomodulation therapy may not influence either the onset of remission or the long-term course of the disease. Nevertheless, immunosuppressive therapy may be considered in patients presenting with severe symptoms who do not spontaneously remit.

Recently, in 2010, Malek et al. [21] reported a novel approach to reduce the load of insulin receptor antibodies. They treated 7 patients with type B insulin resistance syndrome with a new therapeutic protocol consisting of rituximab and cyclophosphamide combined with pulsed corticosteroids. All 7 patients achieved remission, defined as improved hyperglycemia, discontinuation of insulin therapy, and resolution of hyperandrogenism. This new therapeutic approach is promising in the treatment of both type B insulin resistance as well as other autoantibody receptor diseases.

REFERENCES

Autoimmune hypoglycemia and insulin receptor antibodies